NTRA
Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$369.39
+0.84%Year over year
Reported trailing growth
- Revenue
- +37.8%
- EBITDA
- +15.4%
- EBIT
- +1.3%
- EPS
- +28.8%
- Free cash flow
- -31.4%
- Operating cash flow
- +22.2%
Forward estimates
Based on analyst estimates
- Revenue
- +15.3%
- EBITDA
- +107.4%
- EPS
- +53.4%
Three-year CAGR
- Revenue
- +41.1%
- EBITDA
- -48.9%
- EBIT
- -39.4%
- Net income
- -9.3%
- EPS
- +0.7%
- Free cash flow
- +57.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026